{
    "nct_id": "NCT03122886",
    "official_title": "Double-Blinded, Placebo-Controlled Pilot Trial to Explore Whether Lipids Prevent Carboplatin and Oxaliplatin Hypersensitivity Reactions",
    "inclusion_criteria": "* Advanced, incurable cancer\n* 7th or later cycle of intravenous carboplatin or oxaliplatin infusion planned or 4 months after the first cycle of agent (whichever is of longer duration) =< 30 days after registration\n* Anticipated 2 or more subsequent chemotherapy infusions of either carboplatin or oxaliplatin at the time of study registration; NOTE: the dose of carboplatin or oxaliplatin, choice of other chemotherapy, and other ancillary treatment, such as antiemetics, will be left to the discretion of the treating healthcare provider\n* Willing to provide mandatory blood and urine specimens for correlative research; NOTE: can be waived with permission of study chair (documentation such as an email must be provided)\n* Serum creatinine =< 1.5 times the institutional upper limit of normal (ULN); NOTE: can be waived with permission of study chair (documentation such as an email must be provided)\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x the upper limit of normal\n* Triglycerides < 500 mg/dL\n* Alkaline phosphatase =< 3 x the institutional upper limit of normal\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Concurrent liposomal doxorubicin or any other liposomal agent\n* Prior carboplatin or oxaliplatin hypersensitivity reaction\n* Taking aspirin, nonsteroidal anti-inflammatory agents, or zileuton =< 7 days prior to registration; NOTE: can be waived with permission of study chair (documentation such as an email must be provided)\n* Allergy to egg or egg byproducts",
    "miscellaneous_criteria": ""
}